Breaking News

Breaking news filtered in real-time to show only the most impactful headlines for US-listed public companies.

Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress

(TBIO) Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress

What are the next regulatory and commercialization milestones (e.g., Phase 3 initiation, FDA/EMA interactions) and their timing implications for long‑term shareholder value? What are the key efficacy and safety endpoints reported, and how do they compare to existing therapies or competing pipeline candidates? How will the Phase 2 TRANQUILITY trial results influence TBIO's valuation and near‑term stock price?
Symbol: TBIO
Clinical trials
17 days ago
Read more globenewswire

Rosen Law Firm Encourages GeneDx Holdings Corp. Investors to Inquire About Securities Class Action Investigation - WGS

(NASDAQ:WGS) NEW YORK, Aug. 31, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of GeneDx...

What is the market’s perception of the risk compared to peers and how might institutional investors adjust their positions? How could this legal development affect GeneDx's valuation metrics and short‑term price volatility? What is the likely timeline and potential financial exposure from the securities class action investigation?
Symbol: WGS
Lawsuits
17 days ago
Read more prnewswire

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM

(NASDAQ:ALNY) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase...

Could the new data trigger any regulatory updates, reimbursement changes, or partnership opportunities that might impact the company's market valuation? What implications does the 12‑month OLE data have for Alnylam's future revenue forecasts compared to competing ATTR‑CM therapies? How will the presented long-term cardiovascular benefit data for Vutrisiran affect Alnylam's share price and trading volume?
Symbol: ALNY
Clinical trials
17 days ago
Read more businesswire

Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular diseas

(NYSE:NVO) Bagsværd, Denmark, 31 August 2025 – Novo Nordisk today presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Card...

What are the longer‑term implications for payer coverage, pricing strategy, and Novo Nordisk’s growth trajectory in the obesity/cardiovascular therapeutic space? Will this real‑world data cause a shift in market share away from tirzepatide and potentially impact Eli Lilly’s revenue forecasts? How will the 57% reduction in MACE with Wegovy versus tirzepatide affect Novo Nordisk’s share price in the short term?
Symbol: NVO
Clinical trials
17 days ago
Read more globenewswire

Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease

(NYSE:NVO) Bagsværd, Denmark, 31 August 2025 – Novo Nordisk today presented data from the STEER real-world study of evidence gathered from actual patient experiences at the European Society of Card...

When will the STEER study results be reflected in regulatory submissions or labeling, and how might that timing influence the stock valuation in the near and long term? What impact will this cardiovascular outcome data have on Wegovy's market share and pricing relative to tirzepatide and other GLP‑1/dual‑agonist competitors? How will the 57% reduction in MACE risk for Wegovy versus tirzepatide affect Novo Nordisk's revenue forecasts and earnings guidance?
Symbol: NVO
Clinical trials
17 days ago
Read more globenewswire

Novo Nordisk's Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease

(NYSE:NVO) Compared with tirzepatide, Wegovy® (semaglutide) 2.4 mg showed a significant 57% greater reduction in the risk of heart attack, stroke or death from any cause, in people with overweight ...

What short‑term price volatility can we expect for Novo Nordisk’s stock and how should we position relative to competitor stocks like Eli Lilly? How might the efficacy data influence payer reimbursement policies and pricing strategies for Wegovy compared to tirzepatide? Will the 57% risk reduction for Wegovy vs tirzepatide boost Novo Nordisk’s market share in the obesity/diabetes space and drive a price rally?
Symbol: NVO
Clinical trials
17 days ago
Read more prnewswire